Armata Pharmaceuticals, Inc. (ARMP)
CIK 921114 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 37.2M shares as of Aug 6, 2026 (10-Q). Share count fell from 36.6M to 36,710 between Mar 18, 2026 and May 8, 2026, a pattern consistent with a reverse split (roughly 1-for-998); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Exercise Price Two | 4.3M | $3.25 | — | — |
| Exercise Price Four | 2.7M | $5 | — | — |
| Exercise Price One | 1.9M | $3.25 | — | — |
| Exercise Price Three | 1.8M | $5 | — | — |
| Exercise Price Five | 1,200 | $1680 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 10.7M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $2.76 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $2,000 as of Mar 31, 2016.
Rough fully diluted estimate: 47.8M = 37.2M O/S + 10.7M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Secured Term Loan | $25.0M | $30.0M | $1.52 | 8%-14% | ~16.4M sh |
If every note above converted at its tagged price: ~16.4M new shares on 37.2M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 12, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 37.2M | Aug 6, 2026 |
| + Exercise Price Two (if exercised) | 4.3M | Jun 30, 2026 |
| + Exercise Price Four (if exercised) | 2.7M | Jun 30, 2026 |
| + Exercise Price One (if exercised) | 1.9M | Jun 30, 2026 |
| + Exercise Price Three (if exercised) | 1.8M | Jun 30, 2026 |
| + Exercise Price Five (if exercised) | 1,200 | Jun 30, 2026 |
| + Secured Term Loan (if fully converted) | 16.4M | May 12, 2026 |
| Fully diluted estimate | 64.3M | +72.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $100.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ARMP workspace